Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PL Developments Inc.

www.pldevelopments.com

Latest From PL Developments Inc.

US Health Market In 2019: Unfinished Business Leaves Lasting Impression

Examples of unfinished business from 2019 include no legislation passed to reform OTC monograph program; FDA putting off until May the planned publication of an NPRM to allow firms to submit OTC NDAs with extra-label information to help guide consumers' self-selection; and no OTC naloxone for opioid overdose approved even after FDA's unprecedented step of developing model DFLs sponsors could use for their own label comprehension studies.

OTC Drugs Outlook 2019

Teva Divests US OTC Store Brand Portfolio to PL Developments

Israel's Teva has trimmed its OTC portfolio by offloading its US store brands to PL Developments.
United States Health

Teva Gives Up Its Store-Brand OTC Portfolio To PLD

Teva’s US store-brand OTC portfolio including 40 approved and pending ANDA offerings has been acquired by the family-owned PL Developments.  
OTC Drugs Deals

Private Label Competition For Zegerid OTC Sets Sail With Perrigo Launch

Perrigo's omeprazole and sodium bicarbonate capsules indicated for the treatment of frequent heartburn will bear labeling that has been through several updates since the first PPI became available OTC in 2004.

Gastrointestinal Consumer
See All
UsernamePublicRestriction

Register